Several recent studies aimed to investigate the potential synergistic effects of PD-1/PD-L1 blockade therapy with radiotherapy in patients with advanced cancer (3–5), however it remains uncharacterized whether PD-1/PD-L1 blockade therapy, radiotherapy could also be combined with other immunomodulating strategy to achieve maximal therapeutic efficacy particularly for those cancer patients with advanced and metastatic diseases. The gene discussed is CD274; the disease is metastatic neoplasm.